UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

New Approaches to Sepsis: Molecular Diagnostics and Biomarkers

Clinical Microbiology Reviews, 2012-10, Vol.25 (4), p.609-634

2012

Volltextzugriff (PDF)

The late phase of sepsis is characterized by an increased microbiological burden and death rate

Critical care (London, England), 2011-07, Vol.15 (4), p.R183-R183

2011

Volltextzugriff (PDF)

Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study

PloS one, 2012-09, Vol.7 (9), p.e46003-e46003

2012

Volltextzugriff (PDF)

Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis

PLoS medicine, 2012-11, Vol.9 (11), p.e1001338-e1001338

2012

Volltextzugriff (PDF)

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Clinical and translational science, 2022-04, Vol.15 (4), p.854-858

2022

Volltextzugriff (PDF)

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition

Clinical immunology (Orlando, Fla.), 2017-07, Vol.180, p.25-32

2017

Volltextzugriff (PDF)

Family satisfaction in the intensive care unit: a quantitative and qualitative analysis

Intensive care medicine, 2013-06, Vol.39 (6), p.1071-1079

2013

Volltextzugriff (PDF)

Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: A prospective sequential comparison

Critical care medicine, 2011-06, Vol.39 (6), p.1335-1342

2011

Volltextzugriff (PDF)

Perioperative Fluid Therapy With Tetrastarch and Gelatin in Cardiac Surgery—A Prospective Sequential Analysis

Critical care medicine, 2013-11, Vol.41 (11), p.2532-2542

2013

Volltextzugriff (PDF)

The enigma of sepsis

The Journal of clinical investigation, 2003-08, Vol.112 (4), p.460-467

2003

Volltextzugriff (PDF)

Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys

Clinical infectious diseases, 2015-02, Vol.60 (4), p.586-595

2015

Volltextzugriff (PDF)

Novel strategies for the treatment of sepsis

Nature medicine, 2003-05, Vol.9 (5), p.517-524

2003

Volltextzugriff (PDF)

Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial

Critical care (London, England), 2024-06, Vol.28 (1), p.1, Article 210

2024

Volltextzugriff (PDF)

A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a

The Journal of immunology (1950), 2015-02, Vol.194 (3), p.1199-1210

2015

Volltextzugriff (PDF)

End-of-life care in the intensive care unit: A patient-based questionnaire of intensive care unit staff perception and relatives’ psychological response

Palliative medicine, 2015-04, Vol.29 (4), p.336-345

2015

Volltextzugriff (PDF)

Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression

The Journal of immunology (1950), 2003-01, Vol.170 (1), p.503-507

2003

Volltextzugriff (PDF)

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

Intensive care medicine experimental, 2023-06, Vol.11 (1), p.37-37, Article 37

2023

Volltextzugriff (PDF)

Regulatory Effects of iNOS on Acute Lung Inflammatory Responses in Mice

The American journal of pathology, 2003-12, Vol.163 (6), p.2319-2328

2003

Volltextzugriff (PDF)

Complement in Ischemia Reperfusion Injury

The American journal of pathology, 2003-02, Vol.162 (2), p.363-367

2003

Volltextzugriff (PDF)

A novel questionnaire to measure staff perception of end-of-life decision making in the intensive care unit—Development and psychometric testing

Journal of critical care, 2015-02, Vol.30 (1), p.187-195

2015

Volltextzugriff (PDF)

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

Critical care explorations, 2021-11, Vol.3 (11), p.e0577-e0577

2021

Volltextzugriff (PDF)

The Phosphatidylinositol 3-Kinase Signaling Pathway Exerts Protective Effects during Sepsis by Controlling C5a-Mediated Activation of Innate Immune Functions

Journal of Immunology, 2007-05, Vol.178 (9), p.5940-5948

2007

Volltextzugriff (PDF)

Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells

The Journal of immunology (1950), 2002-11, Vol.169 (10), p.5962-5970

2002

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

New Approaches to Sepsis: Molecular Diagnostics and Biomarkers

The late phase of sepsis is characterized by an increased microbiological burden and death rate

Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study

Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition

Family satisfaction in the intensive care unit: a quantitative and qualitative analysis

Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: A prospective sequential comparison

Perioperative Fluid Therapy With Tetrastarch and Gelatin in Cardiac Surgery—A Prospective Sequential Analysis

The enigma of sepsis

Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys

Novel strategies for the treatment of sepsis

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial

A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a

End-of-life care in the intensive care unit: A patient-based questionnaire of intensive care unit staff perception and relatives’ psychological response

Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

Regulatory Effects of iNOS on Acute Lung Inflammatory Responses in Mice

Complement in Ischemia Reperfusion Injury

A novel questionnaire to measure staff perception of end-of-life decision making in the intensive care unit—Development and psychometric testing

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

The Phosphatidylinositol 3-Kinase Signaling Pathway Exerts Protective Effects during Sepsis by Controlling C5a-Mediated Activation of Innate Immune Functions

Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells

Suchergebnisse filtern